CureVac N.V. Stock News
$2.87
4.01%
day before yesterday
Nasdaq,
Dec 20, 10:00 pm CET
CureVac N.V. Stock News
Positive
MarketBeat
●
6 days ago
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
Neutral
Seeking Alpha
●
about one month ago
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants C...
Neutral
Accesswire
●
about one month ago
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO N...
EQS
●
about one month ago
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
AD HOC NEWS
●
about one month ago
CureVac / NL0015436031
Neutral
Accesswire
●
about one month ago
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024.
EQS
●
about one month ago
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen“ im Sinne des United States Private Securities Litigation Reform Act von 1995 darstellen, einschließlich Aussagen, die Meinungen, Erwartungen, Überzeugungen, Pläne, Ziele, Annahmen oder Prognosen der CureVac N.V. und/oder i...
AD HOC NEWS
●
about 2 months ago
CureVac / NL0015436031
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
